Tumor-Infiltrating Lymphocyte Therapy vs Ipilimumab for Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
N. Engl. J. Med 2022 Dec 08;387(23)2113-2125, MW Rohaan, TH Borch, JH van den Berg, Ö Met, R Kessels, MH Geukes Foppen, J Stoltenborg Granhøj, B Nuijen, C Nijenhuis, I Jedema, M van Zon, S Scheij, JH Beijnen, M Hansen, C Voermans, IM Noringriis, TJ Monberg, RB Holmstroem, LDV Wever, M van Dijk, LG Grijpink-Ongering, LHM Valkenet, A Torres Acosta, M Karger, JSW Borgers, RMT Ten Ham, VP Retèl, WH van Harten, F Lalezari, H van Tinteren, AAM van der Veldt, GAP Hospers, MAM Stevense-den Boer, KPM Suijkerbuijk, MJB Aarts, D Piersma, AJM van den Eertwegh, JB de Groot, G Vreugdenhil, E Kapiteijn, MJ Boers-Sonderen, WE Fiets, FWPJ van den Berkmortel, E Ellebaek, LR Hölmich, ACJ van Akkooi, WJ van Houdt, MWJM Wouters, JV van Thienen, CU Blank, A Meerveld-Eggink, S Klobuch, S Wilgenhof, TN Schumacher, M Donia, IM Svane, JBAG HaanenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.